Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$23.1 million.

  • Ascendis Pharma A's Income from Continuing Operations rose 4043.14% to -$23.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$218.5 million, marking a year-over-year increase of 4532.67%. This contributed to the annual value of -$222.9 million for FY2025, which is 4337.04% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Income from Continuing Operations of -$23.1 million as of Q4 2025, which was up 4043.14% from -$62.8 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Income from Continuing Operations high stood at -$23.1 million for Q4 2025, and its period low was -$200.7 million during Q4 2022.
  • In the last 5 years, Ascendis Pharma A's Income from Continuing Operations had a median value of -$112.0 million in 2024 and averaged -$108.9 million.
  • In the last 5 years, Ascendis Pharma A's Income from Continuing Operations crashed by 8524.76% in 2022 and then surged by 6993.03% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Income from Continuing Operations stood at -$121.3 million in 2021, then plummeted by 65.42% to -$200.7 million in 2022, then surged by 59.64% to -$81.0 million in 2023, then soared by 52.12% to -$38.8 million in 2024, then surged by 40.43% to -$23.1 million in 2025.
  • Its Income from Continuing Operations stands at -$23.1 million for Q4 2025, versus -$62.8 million for Q3 2025 and -$35.3 million for Q2 2025.